Expanded indication brings medicine to elderly AML patients who are not eligible for haematopoietic stem cell transplantation and who have >30% myeloblasts in their bone marrow BOUDRY, Switzerland-- -- Celgene International SA rl, a wholly owned subsidiary of Celgene Corporation today announced that that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for an expanded indication of VIDAZAA for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation .